SCHERBAKOV EUGENE A sold $155K of IPGP

SCHERBAKOV EUGENE A sold 1,524 shares of IPG PHOTONICS CORP (IPGP) at an average of $101.55 ($100.43–$106.66, $0.15M total) across 5 trades on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SCHERBAKOV EUGENE A
Published Jul 1, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IPGP
Neutral
medium confidence
Mentioned
$IPGP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPGPNeutralLow
01

Why it matters

A director/10% owner sold shares in multiple trades at $100.43–$106.66 (weighted avg $101.5466) totaling ~$154.8k, executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is primarily a routine compliance event.

03

What to watch

The article provides no context on total insider holdings changes beyond the post-transaction figure, nor any concurrent company-specific catalyst; interpretive value is therefore limited.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-01 after 2026-06-29 insider sale execution

Background

The article is an SEC Form 4 insider transaction disclosure for IPG Photonics (IPGP).

Company-level read

Ticker impact

$IPGPNeutralMedium confidence
Context

IPG Photonics Form 4 shows director/10% owner sold 1,524 shares in open-market trades on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely limited to short-lived sentiment around the filing date.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Minimal—single-company insider sale without accompanying operational/regulatory news.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be read as confidence erosion by some traders, creating short-term sentiment pressure.

Key entities

  • IPG PHOTONICS CORP

    Subject of the Form 4 insider transaction; director/10% owner sold shares under a 10b5-1 plan.

  • SCHERBAKOV EUGENE A

    Director and 10% owner who executed the open-market sale(s).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IPGPMed

Why IPG Photonics (IPGP) shares are falling today

IPG Photonics (IPGP) shares fell 9.8% after Democratic senators called for slowing AI data center development, impacting chipmakers. Micron paused a $4.5B plant in Taiwan due to labor disputes. IPGP is down 15.9% YTD, trading 59.2% below its 52-week high. Rising Treasury yields also weigh on semiconductor stocks.

$IPGPMed

IPG Photonics Corp (IPGP) (Q3 2026) Earnings Call Highlights: Fourth Straight Quarter

IPG Photonics (IPGP) expects Q4 revenue of $265-$295M, with adjusted gross margin declining to 37-40% due to lower tariff refunds. European sales fell 1% YoY, while defense revenue is lumpy. CEO Dr. Mark Gitin sees long-term growth in battery, semiconductor, and medical sectors. CFO Timothy Mammen notes cost pressures but expects gross margin improvements in 2027. Medical and semiconductor are key growth drivers.

$IPGPLow

IPG Photonics (IPGP) Beat Q3 Estimates, Is It Still Below Fair Value?

IPG Photonics (IPGP) reported Q3 2026 sales of $287.5M and net income of $20.27M, beating estimates. Despite this, shares fell 11.46% in 30 days and 11.40% over 1 year. The stock closed at $74.42, with some analysts valuing it 40% below fair value at $124.14, citing growth opportunities. However, its P/E ratio of 114.9x raises valuation concerns compared to industry peers.

MedAI 8/10

IPG Photonics Corporation Q3 2026 Earnings Call Summary

IPG Photonics reported Q3 2026 revenue growth of 15%, driven by industrial and advanced solutions. Advanced Solutions revenue surged 33% YoY, led by semiconductor and defense applications. The company expects medical business growth to double in 2-3 years post-Lumibird Medical acquisition. Q4 guidance accounts for moderation in China's battery capacity additions. The company maintains a strong balance sheet with $926M in cash and no debt.

$IPGPMedAI 8/10

IPG Photonics (IPGP) Q3 2026 Earnings Call Transcript

IPG Photonics (IPGP) reported Q3 2026 earnings, with revenue up 15% YoY to $288M. Industrial Solutions revenue grew 12% YoY, driven by welding and additive manufacturing. Advanced Solutions revenue increased 33% YoY, with strong growth in semiconductor and defense applications. The company announced the acquisition of Lumibird Medical, expected to close in Q4, expanding its medical laser platform. IPGP plans to host an Investor Day on March 2, 2027.